FindTrial
Sign In

A study to identify and characterize preferred factors influencing acceptability and feasibility of potential targeted long-acting injectable ART regimens for children, adolescents and adults living with HIV in India

Global Long-acting Drug Combination Development (GLAD) Project: Preferred User Characteristics Evaluation - GLAD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089655
Enrollment
650
Registered
2025-06-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Interventions

Intervention1: Nil: Nil

Sponsors

National Institutes of Health (NIH)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Added in the summary section

Exclusion criteria

Exclusion criteria: Any individual who meets the following criteria will be excluded from participation in this study: Conditions that would place the individual at increased risk or preclude the individual s full compliance with or completion of the study such as advanced HIV disease or other medical condition that impairs cognition.

Design outcomes

Primary

MeasureTime frame
The study will identify and characterize preferred user characteristics influencing acceptability and feasibility of potential targeted long-acting injectable ART regimens for children, adolescents and adults living with HIV in IndiaTimepoint: Baseline—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDrNKumarasamy

VHS Infectious Diseases Medical Centre

kumarasamy@cartcrs.org9176912007

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026